LEADER 03152oam 22006374a 450 001 9910146264703321 005 20230630033928.0 010 $a9786613267412 010 $a9781283267410 010 $a1283267411 010 $a9780874216714 010 $a0874216710 035 $a(CKB)1000000000442805 035 $a(EBL)769754 035 $a(OCoLC)126804515 035 $a(SSID)ssj0000212288 035 $a(PQKBManifestationID)11196706 035 $a(PQKBTitleCode)TC0000212288 035 $a(PQKBWorkID)10157855 035 $a(PQKB)11379452 035 $a(MiAaPQ)EBC769754 035 $a(MdBmJHUP)muse18186 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54798 035 $a(Perlego)2068197 035 $a(oapen)doab54798 035 $a(EXLCZ)991000000000442805 100 $a20010803e20011988 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aNorthern Navajo Frontier 1860 1900$fRobert S. McPherson 210 $cUtah State University, University Libraries$d2001 210 1$aLogan, Utah :$cUtah State University Press,$d2001. 210 4$dİ2001. 215 $a1 online resource (133 pages) 300 $aOriginally published: Albuquerque : University of New Mexico Press, c1988. 311 08$aPrint version: 9780874214246 320 $aIncludes bibliographical references (p. 119-125) and index. 327 $a1 Setting the Stage --2 Navajos, Utes and the Paiute Connection 1860-80 --3 Monster Slayer Meets the Mormons on the Northern Navajo Frontier, 1870-1900 --4 Navajos, Mormons, and Henry L. Mitchell: Cauldron of Conflict on the San Juan --5 Indians, Anglos, and Ungulates: Resource Competition on the San Juan --6 Boats, Booze, and Barter: Trade on the Norther Navajo Frontier, 1870-1910 --7 Boundaries, Bonanzas, and Bickering: Consolidation of the Northern Navajo Frontier, 1870-1905 --8 Conclusion --Notes --References --Index. 330 $aMcPherson argues that, instead of being a downtrodden group of prisoners, defeated militarily in the 1860s and dependent on the U.S. government for protection and guidance in the 1870s and 80s, the Navajo nation was vigorously involved in defending and expanding the borders of their homelands. This was accomplished not through war nor as a concerted effort, but by an aggressive defensive policy built on individual action that varied with changing circumstances. Many Navajos never made the Long Walk to Bosque Redondo. Instead they eluded capture in northern and western hinterlands and ther-- 606 $aFrontier and pioneer life$zSouthwest, New 606 $aNavajo Indians$xLand tenure 606 $aNavajo Indians$xHistory 615 0$aFrontier and pioneer life 615 0$aNavajo Indians$xLand tenure. 615 0$aNavajo Indians$xHistory. 676 $a979.1004/972 700 $aMcPherson$b Robert S.$f1947-$0801369 801 0$bMdBmJHUP 801 1$bMdBmJHUP 906 $aBOOK 912 $a9910146264703321 996 $aNorthern Navajo Frontier 1860-1900$91802698 997 $aUNINA LEADER 06995nam 22013213u 450 001 9910808713803321 005 20251116164038.0 010 $a1-283-20363-4 010 $a9786613203632 010 $a0-470-92935-9 010 $a0-470-92934-0 035 $a(CKB)2550000000042753 035 $a(EBL)818637 035 $a(OCoLC)746598445 035 $a(SSID)ssj0000534041 035 $a(PQKBManifestationID)12165841 035 $a(PQKBTitleCode)TC0000534041 035 $a(PQKBWorkID)10493413 035 $a(PQKB)10894419 035 $a(MiAaPQ)EBC818637 035 $a(PPN)190360267 035 $a(EXLCZ)992550000000042753 100 $a20131230d2011|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntiviral Drugs $eFrom Basic Discovery Through Clinical Trials 205 $a1st ed. 210 $aHoboken $cWiley$d2011 215 $a1 online resource (470 p.) 300 $aDescription based upon print version of record. 311 08$a1-118-25122-9 311 08$a0-470-45563-2 327 $aANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients 327 $a7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 327 $a14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 327 $a21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 327 $a29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate 330 $aThis book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense so 606 $aAntiviral Agents -- therapeutic use 606 $aAntiviral agents 606 $aClinical Trials as Topic 606 $aDrug Discovery 606 $aDrug Evaluation 606 $aAntiviral agents 606 $aEpidemiologic Studies 606 $aChemistry, Pharmaceutical 606 $aEvaluation Studies as Topic 606 $aInvestigative Techniques 606 $aAnti-Infective Agents 606 $aEpidemiologic Methods 606 $aPharmacology 606 $aTherapeutic Uses 606 $aHealth Care Evaluation Mechanisms 606 $aChemistry 606 $aBiological Science Disciplines 606 $aNatural Science Disciplines 606 $aQuality of Health Care 606 $aPublic Health 606 $aPharmacologic Actions 606 $aEnvironment and Public Health 606 $aHealth Care Quality, Access, and Evaluation 606 $aChemical Actions and Uses 606 $aDelivery of Health Care 606 $aClinical Trials as Topic 606 $aDrug Discovery 606 $aAntiviral Agents 606 $aDrug Evaluation 606 $aHealth & Biological Sciences$2HILCC 606 $aPharmacy, Therapeutics, & Pharmacology$2HILCC 615 4$aAntiviral Agents -- therapeutic use. 615 4$aAntiviral agents. 615 4$aClinical Trials as Topic. 615 4$aDrug Discovery. 615 4$aDrug Evaluation. 615 0$aAntiviral agents. 615 2$aEpidemiologic Studies. 615 2$aChemistry, Pharmaceutical. 615 2$aEvaluation Studies as Topic. 615 2$aInvestigative Techniques. 615 2$aAnti-Infective Agents. 615 2$aEpidemiologic Methods. 615 2$aPharmacology. 615 2$aTherapeutic Uses. 615 2$aHealth Care Evaluation Mechanisms. 615 2$aChemistry. 615 2$aBiological Science Disciplines. 615 2$aNatural Science Disciplines. 615 2$aQuality of Health Care. 615 2$aPublic Health. 615 2$aPharmacologic Actions. 615 2$aEnvironment and Public Health. 615 2$aHealth Care Quality, Access, and Evaluation. 615 2$aChemical Actions and Uses. 615 2$aDelivery of Health Care. 615 2$aClinical Trials as Topic. 615 2$aDrug Discovery. 615 2$aAntiviral Agents. 615 2$aDrug Evaluation. 615 7$aHealth & Biological Sciences 615 7$aPharmacy, Therapeutics, & Pharmacology 676 $a615/.7924 700 $aKazmierski$b Wieslaw M$01671234 702 $aKazmierski$b Wieslaw M. 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910808713803321 996 $aAntiviral Drugs$94033635 997 $aUNINA